Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)

European Journal of Pediatrics

Volumn 156, Issue 10, 1997, Pages 792-794

  Landsmeer Beker, E A ^a   Massa, G G ^a   Maaswinkel Mooy, P D ^a   Van De Kamp, J J P ^a   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Osteogenesis imperfecta; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; OLPADRONIC ACID;

ARTICLE; CASE REPORT; DRUG EFFECT; DRUG USE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OSTEOGENESIS IMPERFECTA; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME;

BODY HEIGHT; BONE DENSITY; CHILD; DIPHOSPHONATES; FOLLOW-UP STUDIES; HUMANS; INFANT; LONG-TERM CARE; MALE; OSTEOGENESIS IMPERFECTA;

EID: 0030848706     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310050715     Document Type: Article

References (13)

1. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363
2. Ferretti JL, Mondelo N, Capozza RF, Cointry GR, Zanchetta JR, Montuori E (1995) Effects of large doses of olpadronate (dimethylpamidronate) on mineral density, cross-sectional architecture, and mechanical properties of rat femurs. Bone 16 [Suppl]:285S-293S
3. Glorieux FH, Travers R, Lanone G (1995) Pamidronate treatment in children with fibrous dysplasia and osteogenesis imperfecta (abstract). Bone 17 [Suppl]:611
4. Hoekman K, Papapoulos SE, Peters ACB, Bijvoet OLM (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952-956
5. Huaux JP, Lokietek W (1988) Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthoped 8:71-72
6. Papapoulos SE (1996) Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, New York, pp 1209-1234
7. Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM (1989) Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 4:775-781
8. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA (1994) Aminohydroxy propylidine bisphosphonate (APD) treatment improves the clinical manifestations of Gaucher's disease. Pediatrics 94:385-389
9. Shapiro JR (1995) Comment on osteogenesis imperfecta. J Bone Miner Res 10:338-339
10. Sillence DO, Senn AS, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116
11. Smith R (1995) Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol 34:68-77
12. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J (1992) Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int 50:36-41
13. Villanueva AR, Frost HM (1970) Bone formation in human osteogenesis imperfecta measured by tetracycline bone labeling. Acta Orthop Scand 41:531-538